Accipiter Biosciences Inc.

SEATTLE, WA · Founded 2023 · Biotech · Private

Computationally designed multifunctional protein therapeutics

Claim this profile

Follows are private to you and power your alerts

Updated · accipiterbio.com

Sector
Biotech
Headquarters
SEATTLE, WA
Founded
2023
Latest Form D
$7.9M, May 2024
Total capital
$8.6M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$8.6M
2 Form D · last May 2024
29 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

20232024FEDERAL ↑EQUITY ↓Cumulative $8.6M1st Form D$650K2nd Form D$7.9M
20232024FEDERAL ↑EQUITY ↓Cumulative $8.6M1st Form D$650K2nd Form D$7.9M

Latest events

  • Private capital raisedForm D · SEC · 2nd filing$7.9M
  • Private capital raisedForm D · SEC · 1st filing$650K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Founders and team

From SEC Form D filings
  • Heather GorhamDirectorNamed in SEC Form D filings
  • Hector AranoExecutive Officer, Director, PromoterNamed in SEC Form D filings
  • Hector De Jesus Rincon AranoExecutive Officer, PromoterNamed in SEC Form D filings
  • Javier CastellanosExecutive Officer, Director, PromoterNamed in SEC Form D filings
  • Jiaping GuDirectorNamed in SEC Form D filings
  • Jose Antonio Mesa CejudoDirectorNamed in SEC Form D filings
Show all 8 people
  • Matthew BickExecutive Officer, Director, PromoterNamed in SEC Form D filings
  • William ArthurExecutive Officer, Director, PromoterNamed in SEC Form D filings

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

  • Model Medicines, Inc.Similar federal contract value in Biotech · null in contracts
  • Vetmab Biosciences, Inc.Similar federal contract value in Biotech · null in contracts
  • Mercury Bio, Inc.Similar federal contract value in Biotech · null in contracts
  • LAVO LIFE SCIENCES INCSimilar federal contract value in Biotech · null in contracts
  • Violet TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • ELIXIRGEN, LLCSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .